4//SEC Filing
Topper James N 4
Accession 0000950170-24-107536
CIK 0001776111other
Filed
Sep 16, 8:00 PM ET
Accepted
Sep 17, 8:11 PM ET
Size
16.4 KB
Accession
0000950170-24-107536
Insider Transaction Report
Form 4
Frazier Life Sciences X, L.P.
10% Owner
Transactions
- Purchase
Common Stock
2024-09-16$16.00/sh+625,000$10,000,000→ 4,552,774 total - Conversion
Common Stock
2024-09-16+3,927,774→ 3,927,774 total - Conversion
Series A Convertible Preferred Stock
2024-09-16−18,922,852→ 0 total→ Common Stock (1,574,005 underlying) - Conversion
Series B Convertible Preferred Stock
2024-09-16−28,297,265→ 0 total→ Common Stock (2,353,769 underlying)
Topper James N
10% Owner
Transactions
- Conversion
Common Stock
2024-09-16+3,927,774→ 3,927,774 total - Conversion
Series B Convertible Preferred Stock
2024-09-16−28,297,265→ 0 total→ Common Stock (2,353,769 underlying) - Conversion
Series A Convertible Preferred Stock
2024-09-16−18,922,852→ 0 total→ Common Stock (1,574,005 underlying) - Purchase
Common Stock
2024-09-16$16.00/sh+625,000$10,000,000→ 4,552,774 total
FHMLS X, L.L.C.
10% Owner
Transactions
- Conversion
Series A Convertible Preferred Stock
2024-09-16−18,922,852→ 0 total→ Common Stock (1,574,005 underlying) - Conversion
Common Stock
2024-09-16+3,927,774→ 3,927,774 total - Conversion
Series B Convertible Preferred Stock
2024-09-16−28,297,265→ 0 total→ Common Stock (2,353,769 underlying) - Purchase
Common Stock
2024-09-16$16.00/sh+625,000$10,000,000→ 4,552,774 total
FHMLS X, L.P.
10% Owner
Transactions
- Purchase
Common Stock
2024-09-16$16.00/sh+625,000$10,000,000→ 4,552,774 total - Conversion
Series A Convertible Preferred Stock
2024-09-16−18,922,852→ 0 total→ Common Stock (1,574,005 underlying) - Conversion
Common Stock
2024-09-16+3,927,774→ 3,927,774 total - Conversion
Series B Convertible Preferred Stock
2024-09-16−28,297,265→ 0 total→ Common Stock (2,353,769 underlying)
Footnotes (3)
- [F1]Each share of Series A Convertible Preferred Stock, Series B Convertible Preferred Stock and Series C Convertible Preferred Stock (collectively, the "Preferred Stock") was convertible into Common Stock on a one-for-12.0221 basis at any time at the option of the holder, and automatically converted into the number of shares shown in Column 7 immediately prior to the closing of the Issuer's initial public offering on September 16, 2024. The Preferred Stock had no expiration date.
- [F2]These securities are held of record by Frazier Life Sciences X, L.P. ("FLS X"). FHMLS X, L.P. is the general partner of FLS X, and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. Patrick Heron and James Topper, M.D., Ph.D., are the sole managing members of FHMLS X, L.L.C. and share voting and investment power of the securities held by FLS X, and as a result, may be deemed to have beneficial ownership over such securities. Mr. Heron and Dr. Topper disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.
- [F3]Reflects shares purchased in the Issuer's initial public offering.
Documents
Issuer
MBX Biosciences, Inc.
CIK 0001776111
Entity typeother
Related Parties
1- filerCIK 0001341382
Filing Metadata
- Form type
- 4
- Filed
- Sep 16, 8:00 PM ET
- Accepted
- Sep 17, 8:11 PM ET
- Size
- 16.4 KB